In yesterday’s Wall Street session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares traded at $15.14, down -16.81% from the previous session.
FDMT stock price is now -36.96% away from the 50-day moving average and -28.83% away from the 200-day moving average. The market capitalization of the company currently stands at $782.74M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $459, Barclays recently initiated with Overweight rating for 4D Molecular Therapeutics Inc (NASDAQ: FDMT). On April 15, 2024, Barclays recently initiated its ‘Overweight’ rating on the stock quoting a target price of $45, while ‘Goldman’ rates the stock as ‘Buy’
In other news, Bizily Scott, Chief Legal Officer sold 1,750 shares of the company’s stock on Jul 16 ’24. The stock was sold for $47,442 at an average price of $27.11. Upon completion of the transaction, the Chief Legal Officer now directly owns 6,781 shares in the company, valued at $0.1 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 11 ’24, Chief Legal Officer Bizily Scott sold 1,996 shares of the business’s stock. A total of $49,900 was realized by selling the stock at an average price of $25.00. This leaves the insider owning 6,781 shares of the company worth $0.1 million. A total of 15.79% of the company’s stock is owned by insiders.
During the past 12 months, 4D Molecular Therapeutics Inc has had a low of $9.44 and a high of $36.25. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 32.65, and a quick ratio of 32.65. The fifty day moving average price for FDMT is $23.5828 and a two-hundred day moving average price translates $21.7554 for the stock.
The latest earnings results from 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was released for 2024-03-31. The net profit margin was -436.30% and return on equity was -33.00% for FDMT. The company reported revenue of $28000.0 for the quarter, compared to $0.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -90.6 percent.
